Cancer Research UK logo.
SearchDonate
  • Search

A trial of MK-6482 for kidney cancer (MK-6482-005)

Overview

Cancer types:

Kidney cancer, Renal cell cancer, Secondary cancers

Status:

Closed

Phase:

Phase 3

Details

This trial is comparing a drug called MK-6482 with everolimus for kidney cancer.

It is open to people with kidney cancer that has spread to another part of the body or to the surrounding tissue. And it can’t be removed with surgery.

Recruitment start: 8 October 2020

Recruitment end: 31 December 2021

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Naveed Sarwar

Supported by

Merck Sharp & Dohme Ltd

Last reviewed: 31 Dec 2021

CRUK internal database number: 17242

Help and support